Johnson & Johnson is doing something unusual post-earnings: options traders have abandoned their defensive posture at a pace that has driven the put/call ratio to its lowest reading in a full year.
The options signal is the week's standout. The put/call ratio has collapsed to 0.67 — the 52-week low, against a 52-week high of 1.13. More telling is the z-score: at -2.7 standard deviations below the 20-day mean of 0.87, this is the most call-heavy tilt in at least a year. That kind of shift, arriving days after a 1.5% earnings-day decline, points to a market that has digested the Q2 disappointment and rotated toward positioning for upside. Contrast that with mid-June, when the ratio was running above 1.05 — the options book then looked meaningfully more cautious than it does today.
Short interest tells a quieter story, and it deserves a separate read. At 1.3% of free float, the short position is not large enough to drive the stock. What is notable is the direction: shorts have added roughly 21% in the past month, with the weekly pace of accumulation now running at 7.3%. That's a steady build, not a scramble. The borrow market imposes no friction — availability is effectively unlimited, and cost to borrow at 0.35% is negligible. The short build is a view, not a squeeze setup.
The Street is nearly unanimous in its direction, even if it is split on conviction. Following the Q2 print, Morgan Stanley lifted its Overweight target to $294, Wells Fargo raised its Overweight target to $272, and Raymond James moved its Outperform target to $265. The consensus mean now sits at $270.59 against a current price of $250.61 — implying roughly 8% to target. The lone holdout in tone is BofA, which maintains a Neutral rating despite lifting its target to $263. The bull case rests on pipeline depth across immunology and oncology and disciplined capital allocation. Bears point to patent expirations, medtech competition in cardiovascular, and litigation costs that remain an open variable. Valuation has re-rated modestly over the past month — the P/E has expanded 1.3 turns to 20.4x, and the P/B has gained 0.48 to 6.35x — but neither multiple looks stretched against a large-cap pharma backdrop. EPS momentum ranks in the 68th percentile over 30 days and 80th percentile on forward year-over-year growth estimates, providing some fundamental support for the multiple expansion.
Among peers, the week's performance divergence is worth noting. MRK gained 4.5% on the week and BMY added nearly 7%, both comfortably outpacing JNJ's 1.3% decline. RPRX was up 4.9%. JNJ has underperformed the peer group through the post-earnings window — consistent with the pattern from the prior note, where the stock clawed back from its $247 low but has not fully rejoined the sector's momentum. The gap between JNJ and its correlated names is narrowing, though, and the one-day performance on July 21 — up 0.72% — moved roughly in line with the group.
On the insider front, EVP Vanessa Broadhurst sold 23,054 shares on July 20 for roughly $5.8 million. The 90-day net insider position is positive in share terms at 44,056 shares, though that figure is driven by an award grant rather than open-market buying. All recent cash transactions have been sales — the CFO sold in February, and two other EVPs have followed. None of the trades carry a high significance score, and none suggest distress, but the pattern of consistent selling into price strength is worth tracking as the stock attempts to close the gap toward consensus.
What to watch next: the next earnings date is October 13, leaving a full quarter for the gap between $250.61 and the $270 consensus to either close through price or widen through further target cuts — and whether the current call-heavy options posture holds or fades as that cycle approaches.
See the live data behind this article on ORTEX.
Open JNJ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
